The article highlights the potential of lacosamide, a third-generation anticonvulsant, in treating facial pain. The study retrospectively reviewed three patients with refractory facial pain of various etiologies, and all three showed significant improvement after treatment with lacosamide, with no reported side-effects. This suggests lacosamide could be an alternative treatment for patients who do not tolerate or respond to standard treatments for facial pain, which often come with intolerable side effects. While the study is limited by its small sample size and retrospective nature, it provides promising evidence for further research into the use of lacosamide for the treatment of facial pain. This could potentially improve the quality of life for patients suffering from this debilitating condition.

An 82-year-old male experienced an abrupt personality change after taking lacosamide, a medication used for epilepsy, according to a case study. The patient, who had been experiencing neurological follow-up since 2010 due to epilepsy secondary to haemorrhagic stroke, became "gentle", "calm" and apologetic for past aggression after taking the medication. However, he also made sexualised remarks to his home nurses. After the medication was withdrawn, the patient reverted to his previous vindictive and aggressive character but did not make any inappropriate remarks. The study raises concerns about the potential behavioural and personality impacts of medications and highlights the need for vigilant monitoring of patients for changes in behaviour.

A review of multiple clinical trials on lacosamide, an anti-epileptic drug, found that it was effective as adjunctive therapy for partial-onset seizures and monotherapy for patients with epilepsy. The drug had a generally favorable safety profile, but rare cardiac side effects such as ventricular tachycardia and complete atrioventricular block were noted. Lacosamide was also found to have psychiatric and behavioral side effects in some adult patients with epilepsy. Overall, the review suggests that lacosamide is a valuable treatment option for epilepsy, but caution is needed when monitoring for potential cardiac and behavioral side effects.

Only 2 events were considered as possibly related to lacosamide; both occurred in the same patient at a dose of 200 mg/day lacosamide and resulted in the patient being withdrawn from the trial. Of these seven patients, one patient had dizziness and nausea, one had chest pain and nausea, two had ECG changes, one had dizziness, fatigue, and tinnitus, one patient was hospitalized with possible cerebrovascular accident and convulsion, and one patient had an accidental overdose Number of patients enrolled and entering the Titration Period Titration Period 100 mg/day 69 Lacosamide prescribed dose 200 mg/day 300 mg/day 400 mg/day 61 53 45 Discontinued: Adverse events; Consent withdrawn Maintenance Period 1 14 18 Discontinued:: Adverse events; Other reasons 40 Extension Period Discontinued:Adverse events; Other reasons < 6 months 6 - < 12 months 12 - < 18 months ≥18 months 0 0 1 0 1 3 4 2 5 14 2 Fig. Of the two patients with ECG changes who were withdrawn from this trial, one patient experienced a QTc value of 501 ms compared with the baseline value of 436 ms; the second patient developed a QRS of 124 ms and a heart rate of 55 beats/min against baseline values of 112 ms and 78 beats/min. At the end of three months of treatment with lacosamide, 61% of patients reported feeling ''much better" as assessed by Patient's Global Impression of Change in pain, compared with baseline.

Lacosamide is an antiepileptic drug that has recently been investigated for neuropathic pain relief, although it failed to get approval for painful diabetic peripheral neuropathy from either the Food and Drug Administration or the European Medicines Agency. Objectives To evaluate the analgesic efficacy and adverse effects of lacosamide in the management of chronic neuropathic pain or fibromyalgia. The number needed to treat to harm for adverse event withdrawal was 11 for lacosamide 400 mg and 4 for the 600 mg dose. PICOs Lacosamide for neuropathic pain and fibromyalgia in adults Antiepileptic drugs like lacosamide are commonly used for treating neuropathic pain, usually defined as pain due to damage to nerves.

Neuropathic pain is a difficult-to-treat condition that requires new and effective drugs. A review of preclinical and clinical data has been conducted on the potential of lacosamide as an analgesic agent. The data suggest that while the majority of published human data relate to the use of lacosamide for painful diabetic neuropathy, further investigation is needed for other neuropathic pain conditions. Although the extent of pain relief produced has not been sufficient for a product license for diabetic neuropathy, there remains a need for novel approaches to treat neuropathic pain, and lacosamide may hold promise in this area. Overall, the importance of continued research into this area is critical to help alleviate the suffering of patients with neuropathic pain.

Clinical trial data on people with drug resistant epilepsy suggest LCM has a response rate of 33-45% at doses between 200 and 400 mg daily in individuals with refractory focal seizures, with about 3% of people seizure free in these short studies. We assessed the long-term retention of treatment with LCM in a large cohort of people with mainly medically refractory epilepsy from a single tertiary centre to understand better the efficacy and tolerability of LCM in clinical practice, to consider its place in the current antiepileptic armamentarium. Exclusion criteria comprised LCM started for reasons other than epilepsy, people who did not start LCM and, to avoid survival bias, people who had LCM started elsewhere and those who had taken part in a Results Three hundred and eighty people started lacosamide during the study period and met the inclusion criteria. In an audit check of two consecutive weeks of outpatient consultations, we identified one person who was not included, suggesting that potentially up to 19 people Discussion We assessed the efficacy and tolerability of LCM in a large cohort of people with medically refractory epilepsy, most of whom could be described as drug resistant according the latest guidelines of the International League Against Epilepsy, including individuals with learning disabilities and psychiatric co-morbidities.

These features make LCM a particularly attractive option for patients with difficult-to-treat epilepsy. One had not improved with vagus nerve stimulation, seizures in another patient regressed after epilepsy surgery, and 3 had not benefited from the ketogenic diet. We have described our experience with the use of LCM, a novel anticonvulsant, in pediatric patients with pharmacoresistant focal epilepsy. Our group of patients had a long history of epilepsy, had Cited by Safety and tolerability of adjunctive lacosamide in a pediatric population with focal seizures - An open-label trial 2019, Seizure The availability of lacosamide as oral tablet, oral solution, and intravenous solution provides added therapeutic flexibility, with the oral solution potentially being useful for children who may find it difficult to swallow tablets.

Aside from the possible psychiatric and behavioral side effects experienced by some patients, LEV has a high therapeutic index and wide margin of safety as compared with other AEDs; and it has been widely used in elderly patients with epilepsy in the last decade. Seizure frequency, at baseline Patients In this retrospective study, 22 patients on LCM and 24 patients on LEV were enrolled. Patients on LCM were comparable with LEV patients in terms of demographic data; moreover, Discussion The purpose of this study was to evaluate long-term use of LCM as monotherapy compared with LEV monotherapy in elderly patients. Described a LCM good outcome, efficacy and tolerability both in patients whose seizures were naive to AED therapy and those whose seizures had Conclusion Considering the high rate of comorbidities and the risk of drug-drug interactions in elderly patients having focal onset seizures, the efficacy and tolerability of the LCM and LEV monotherapy was remarkably favorable, even at low doses, as seizure freedom persisted in more than half of patients at long-term follow-up.

Optimal combinations of lacosamide with other types of AEDs have been investigated to a limited extent: the efficacy of lacosamide as adjunctive therapy to treatment with other sodium channel blockers or non-SCBs was evaluated in a post hoc analysis of the three pivotal trials. Open-label extension studies of the pivotal lacosamide phase II/III trials of up to 5 years are ongoing , , , , although patients in these trials had to meet strict entry criteria into the randomized blinded phases of the studies before going Conclusions The RELACOVA study is the largest observational study of lacosamide in patients with partial epilepsy conducted in the real-world setting. Vicente Villanueva has participated in advisory boards or pharmaceutical Cited by Safety and tolerability of adjunctive lacosamide in a pediatric population with focal seizures - An open-label trial 2019, Seizure Furthermore, a post hoc analysis of a placebo-controlled, double-blind trial showed a higher incidence of drug-related TEAEs with lacosamide in children and adolescents taking concomitant SCB AEDs compared with those not taking SCB AEDs. Data in adults have shown inconsistent findings on tolerability and efficacy of lacosamide with or without concomitant SCB AEDs [37-46]. The results from this prospective, phase II, open-label, fixed-titration trial support the safety and tolerability of adjunctive lacosamide at doses up to 12 mg/kg/day in pediatric patients with focal seizures.